Bright Minds Biosciences exploded in the stock market today. The neuropsychiatric disorder treatment company has quietly traded sideways for the better part of the last few months. But this week shares surged following more attention on psychedelic stocks, thanks to MindMed.
The company specializes in drug development designed to leverage therapeutic aspects of psychedelics and serotonergic compounds. Its recent catalysts include a management shakeup and the departure of Dr. Alan Kozikowski as Chief Scientific Offer earlier this summer.
But it may be safe to say that the big move for DRUG stock has more to do with industry sentiment than anything else. In addition, the psychedelic stock is also a low float name as most outlets put this figure below 10 million shares. In this case, it isn't a bad idea to know how to handle volatile trading trends. With low float penny stocks, the moves lower can happen just as quickly as the spikes higher.
The company specializes in drug development designed to leverage therapeutic aspects of psychedelics and serotonergic compounds. Its recent catalysts include a management shakeup and the departure of Dr. Alan Kozikowski as Chief Scientific Offer earlier this summer.
But it may be safe to say that the big move for DRUG stock has more to do with industry sentiment than anything else. In addition, the psychedelic stock is also a low float name as most outlets put this figure below 10 million shares. In this case, it isn't a bad idea to know how to handle volatile trading trends. With low float penny stocks, the moves lower can happen just as quickly as the spikes higher.
Recent DRUG News
- Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/26/2026 11:18:47 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 09:02:15 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 04:36:39 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/13/2026 01:44:13 AM
- Bright Minds Biosciences to Present at Upcoming Conferences • GlobeNewswire Inc. • 02/25/2026 09:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:22:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2026 11:04:46 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2026 09:11:45 PM
- Bright Minds Biosciences Announces Closing of US$175 Million Public Offering • GlobeNewswire Inc. • 01/09/2026 04:56:05 PM
- Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock • GlobeNewswire Inc. • 01/08/2026 02:33:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/07/2026 10:27:57 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 01/07/2026 08:16:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/07/2026 02:54:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/06/2026 10:27:08 PM
- Bright Minds Biosciences Announces Launch of US$100 Million Public Offering • GlobeNewswire Inc. • 01/06/2026 09:00:00 PM
- Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) • GlobeNewswire Inc. • 01/06/2026 12:16:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2026 10:25:50 PM
- Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 • GlobeNewswire Inc. • 01/05/2026 09:30:00 PM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 12/23/2025 10:27:05 PM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 12/23/2025 10:26:37 PM
- Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting • GlobeNewswire Inc. • 11/25/2025 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2025 10:11:25 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 11/17/2025 08:58:53 PM
- Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) • GlobeNewswire Inc. • 11/17/2025 11:50:00 AM
